GLP-1-A candidate humoral mediator for glucose control after roux-en-y gastric bypass

Diabetes

Volumn 63, Issue 2, 2014, Pages 287-289

  Schirra, Jörg ^a   Göke, Burkhard ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ANTIDIABETIC ACTIVITY; BLOOD GLUCOSE MONITORING; CALORIC RESTRICTION; GLUCAGON RELEASE; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; NOTE; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; STOMACH BYPASS; FEMALE; MALE; METABOLISM;

FEMALE; GASTRIC BYPASS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; MALE;

EID: 84893123758     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1660     Document Type: Note

References (25)

1. Gregg EW, Cheng YJ, Narayan KM, Thompson TJ, Williamson DF. The relative contributions of different levels of overweight and obesity to the increased prevalence of diabetes in the United States: 1976-2004. Prev Med 2007;45:348-352
2. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012;367:695-704
3. Dixon JB, le Roux CW, Rubino F, Zimmet P. Bariatric surgery for type 2 diabetes. Lancet 2012;379:2300-2311
4. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012;366:1577-1585
5. Isbell JM, Tamboli RA, Hansen EN, et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care 2010;33:1438-1442
6. Odstrcil EA, Martinez JG, Santa Ana CA, et al. The contribution of malabsorption to the reduction in net energy absorption after long-limb Rouxen-Y gastric bypass. Am J Clin Nutr 2010;92:704-713
7. Goktas Z, Moustaid-Moussa N, Shen CL, Boylan M, Mo H, Wang S. Effects of bariatric surgery on adipokine-induced inflammation and insulin resistance. Front Endocrinol (Lausanne) 2013;4:69
8. Laferrere B, Reilly D, Arias S, et al. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med 2011;3:80re2
9. Schirra J, Katschinski M, Weidmann C, et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996; 97:92-103
10. Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:2479-2485
11. Shah M, Law JH, Micheletto F, et al. Contribution of endogenous glucagonlike peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes 2014;63:483-493
12. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M. Exendin (9-39) amide is an antagonist of glucagon-like peptide-1(7-36) amide in humans. J Clin Invest 1998;101:1421-1430
13. Schirra J, Nicolaus M, Roggel R, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006;55:243-251
14. Nicolaus M, Brödl J, Linke R, Woerle HJ, Göke B, Schirra J. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab 2011;96: 229-236
15. Woerle HJ, Carneiro L, Derani A, Göke B, Schirra J. The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes. Diabetes 2012;61: 2349-2358
16. Salehi M, Prigeon RL, D'Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 2011;60:2308-2314
17. Jørgensen NB, Dirksen C, Bojsen-Møller KN, et al. Exaggerated glucagonlike peptide 1 response is important for improved b-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 2013;62:3044-3052
18. Jiménez A, Casamitjana R, Viaplana-Masclans J, Lacy A, Vidal J. GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care 2013;36:2062-2069
19. Orskov L, Holst JJ, Møller J, et al. GLP-1 does not not acutely affect insulin sensitivity in healthy man. Diabetologia 1996;39:1227-1232
20. Ryan AS, Egan JM, Habener JF, Elahi D. Insulinotropic hormone glucagonlike peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. J Clin Endocrinol Metab 1998;83: 2399-2404
21. Schirra J, Morper M, Nicolaus M, Woerle HJ, Göke B. The efficacy of exendin(9-39) amide as a GLP-1 receptor antagonist in human. Gut 2008; 57:A85
22. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 2013;36:2175-2182
23. Holst JJ. Postprandial insulin secretion after gastric bypass surgery: the role of glucagon-like peptide. Diabetes 2011;60:2203-2205
24. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993;36:857-862
25. Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, Göke B. GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil 2009;21:609-618, e21-e22